Ryan J. Sullivan, MD, on Advanced Solid Tumors: Antitumor Activity With COM701 Plus Nivolumab

May 08, 2020 By The ASCO Post Staff

Ryan J. Sullivan, MD, of Massachusetts General Hospital Cancer Center, discusses early results on COM701, a first-in-class immune checkpoint inhibitor, which showed preliminary antitumor activity as a monotherapy and in combination with nivolumab in a variety of heavily pretreated patients with advanced or metastatic solid tumors (Abstract CT031).

Related Content